Pharmaceutical - Diabetes


Current filters:


Popular Filters

176 to 200 of 399 results

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA


US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

High out-of-pocket costs for DPP-IV inhibitors and GLP-1 analogues greatly limit prescribing in Brazil, Mexico and Argentina


Premium-priced DPP-IV inhibitors and GLP-1 analogues used in the treatment of type 2 diabetes lack nationwide…

DiabetesMarkets & MarketingPharmaceuticalPricingSouth America

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide


Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

FDA approves Boehringer and Lilly's Tradjenta and Jentadueto labeling to reflect pancreatitis risk


German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June…

Boehringer IngelheimDiabetesEli LillyJentaduetoNorth AmericaPharmaceuticalRegulationTradjenta

Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that its new diabetes products Nesina…

DiabetesKazanoMarkets & MarketingNesinaNorth AmericaOseniPharmaceuticalTakeda Pharmaceuticals

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds


Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

Negative US patent ruling for Novo Nordisk on Prandin


Denmark-based insulin giant Novo Nordisk (NOV: N) says that the US Court of Appeals for the Federal Circuit…

DiabetesGenericsLegalNovo NordiskPatentsPharmaceuticalPrandin

Eli Lilly exercises rights to diabetes drug candidate TT-401 from Transition Therapeutics


Canada's Transition Therapeutics (TSX: TTH) announced this morning (June 17) that US drug major Eli Lilly…

DiabetesEli LillyLicensingPharmaceuticalTransition TherapeuticsTT-401

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research


Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

Data on Novo Nordisk's Victoza further supporting safety presented at expert workshop


Danish Insulin giant Novo Nordisk (NOV: N) presented data further supporting the safety of Victoza (liraglutide…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

American Diabetes Association calls for independent review of incretin-based therapy


The American Diabetes Association is asking all pharmaceutical companies involved in the development…

DiabetesJanuviaMerck & CoPharmaceuticalRegulationResearch

Majority vote from FDA advisory panel to ease restrictions on GSK's Avandia


A joint advisory committee to the US Food and Drug Administration (FDA) voted to continue to make UK…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

Zydus' diabetes drug Lipaglyn becomes India's first NCE to reach the market


Indian drugmaker Zydus Cadila today (June 5) made a breakthrough in its research efforts with Lipaglyn…

Asia-PacificDiabetesLipaglynPharmaceuticalRegulationZydus Cadila

GW Pharma posts six-month results; progresses cannabinoid pipeline including into diabetes and UC


UK biopharma company GW Pharmaceuticals (AIM: GWP), which is developing and commercializing novel therapeutics…

DiabetesFinancialGastro-intestinalsGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Novo Nordisk files Tresiba/Victoza combo IDegLira for EU approval


Danish insulin giant Novo Nordisk (NOV: N) said today (May 31) that it has submitted a marketing authorization…

DiabetesEuropeIDegLiraNovo NordiskPharmaceuticalRegulationTresibaVictoza

UK's NICE backs NHS use of Bristol-Myers/AstraZeneca's Forxiga


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today (May 30) issued…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial


Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

FDA allows marketing of first A1c test labeled for diagnosing diabetes, from Roche


The US Food and Drug Administration yesterday (May 23) announced that it is allowing marketing of the…

Cobas Integra 800DiabetesPharmaceuticalRegulationRoche

Positive new data on Novartis' Galvus in elderly type 2 diabetes patients


Results of the INTERVAL study were published on line in The Lancet today (May 23) and for the first time…


176 to 200 of 399 results

Back to top